antiviral and associated therapy - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.03 [0.96, 1.10]< 10%11 studies (11/-)22.1 %some concernlow moderatecrucial-
death or transfer to ICU 1.09 [0.99, 1.20]< 10%1 study (1/-)4.0 %some concernnot evaluable moderatecrucial-
deaths 0.99 [0.94, 1.04]< 10%40 studies (40/-)67.4 %some concerncritical moderatecrucial-
deaths (time to event analysis only) 0.96 [0.87, 1.06]< 143%10 studies (10/-)77.9 %some concernlow moderatecrucial-
clinical deterioration 1.06 [0.79, 1.42]< 10%7 studies (7/-)34.6 %some concernnot evaluable moderateimportant-
clinical improvement 1.24 [1.07, 1.44]> 143%13 studies (13/-)99.8 %some concernlow moderateimportant-
clinical improvement (14-day) 1.10 [0.93, 1.31]> 143%16 studies (16/-)86.9 %some concernlow moderateimportant-
clinical improvement (28-day) 1.24 [1.03, 1.50]> 154%9 studies (9/-)98.8 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.12 [0.95, 1.32]> 136%11 studies (11/-)90.3 %some concerncritical moderateimportant-
clinical improvement (time to event analysis only) 1.24 [1.14, 1.35]> 10%10 studies (10/-)100.0 %some concernlow moderateimportant-
death or ventilation 1.02 [0.95, 1.10]< 120%8 studies (8/-)28.5 %some concernnot evaluable moderateimportant-
hospital discharge 1.00 [0.93, 1.08]> 130%8 studies (8/-)54.4 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.97 [0.77, 1.21]< 127%14 studies (14/-)62.1 %some concernlow moderateimportant-
mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.17 [0.42, 3.26]> 116%3 studies (3/-)62.1 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.09 [0.01, 0.78]> 10%2 studies (2/-)1.5 %some concernnot evaluable moderateimportant-
viral clearance 1.43 [0.99, 2.05]> 163%10 studies (10/-)97.2 %some concernlow moderateimportant-
viral clearance (time to event analysis only) 1.32 [1.03, 1.69]> 10%2 studies (2/-)98.6 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.99 [0.93, 1.06]> 10%7 studies (7/-)40.5 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.01 [0.84, 1.21]> 128%8 studies (8/-)53.7 %some concernnot evaluable moderateimportant-
ICU admission 0.78 [0.47, 1.30]< 10%7 studies (7/-)82.8 %some concernnot evaluable moderatenon important-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %some concernnot evaluable moderatenon important-
recovery 1.10 [0.94, 1.29]> 160%4 studies (4/-)89.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %lownot evaluable highimportant-
cardiac arrest 1.92 [0.35, 10.49]< 10%1 study (1/-)22.7 %some concernnot evaluable moderateimportant-
related SAE (TRSAE) 1.24 [0.50, 3.11]< 10%1 study (1/-)32.0 %some concernnot evaluable moderateimportant-
serious adverse events 0.84 [0.69, 1.03]< 15%17 studies (17/-)95.5 %some concernlow moderateimportant-
adverse events 1.68 [1.22, 2.33]< 171%14 studies (14/-)0.1 %some concernlow moderatenon important-
arrhythmia 0.91 [0.72, 1.15]< 10%3 studies (3/-)78.1 %some concernnot evaluable moderatenon important-
deep vein thrombosis 0.62 [0.23, 1.64]< 10%2 studies (2/-)83.1 %some concernnot evaluable moderatenon important-
elevated liver enzymes 0.58 [0.34, 0.97]< 16%2 studies (2/-)